The effect of memantine on fatigue in patients with Multiple Sclerosis

Comparison of effectiveness of memantine and vitamin B1 in fatigue of patients with multiple sclerosis?

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240118060725N1

Enrollment

Registered

2024-02-14

Start date

2024-03-20

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis. Multiple sclerosis

Interventions

Intervention 1: intervention group:Memantine 5 mg tablets by Hacim company .First daily for a week,then one every 12 hours for 3 months and orally. This drug is a competitive NMDA glutamate antagonis

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Age 20-50 years EDSS between 0-5 Relapsing-Remitting MS Grade 3 or 4 fatigue according to the questionnaire?

Exclusion criteria

Exclusion criteria: Use of Modafinil, Ritalin or Amantadine History of seizures or kidney disease Taking selective serotonin reuptake inhibitor (SSRI) Recent attack within the last 3 months Use of Dalfira

Design outcomes

Primary

Measure	Time frame
Examining the degree of fatigue based on the Modified Fatigue Impact Scale questionnaire. Timepoint: Comparison of fatigue before and 3 months after starting memantine and placebo. Method of measurement: Modified Fatigue Impact Scale questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Jafari Chamandani

Qazvin University of Medical Sciences

fatemejafari78@gmail.com+98 28 3333 2930

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026